September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
The state of gene therapies
Author Affiliations & Notes
  • Wilson Bryan
    Office of Cellular, Tissue, and Gene Therapies, FDA, Silver Spring, Maryland, United States
    Office of Cellular, Tissue, and Gene Therapies, CBER, Silver Spring, Maryland, United States
  • Footnotes
    Commercial Relationships   Wilson Bryan, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, No Pagination Specified. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wilson Bryan; The state of gene therapies. Invest. Ophthalmol. Vis. Sci. 201657(12):.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Presentation Description : This presentation describes the current state of gene therapies, from the perspective of the Director, Division of Clinical Evaluation and Pharmacology / Toxicology, Office of Cellular, Tissue, and Gene Therapies (OCTGT), Center for Biologics Evaluation and Research (CBER), United States Food and Drug Administration (FDA). Topics covered include regulatory perspectives on the challenges and successes that have been seen with gene therapies for a variety of indications, including ophthalmologic disorders.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.